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Inhibition of the angiopoietin/Tie2 axis
induces immunogenic modulation, which
sensitizes human tumor cells to immune
attack
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Abstract
Background: The angiopoietin/Tie2 pathway is an attractive target for cancer therapy due to its well-known role
in regulating angiogenesis. Trebananib, a recombinant peptide-Fc fusion protein, or peptibody, that binds to
angiopoietin-1 (Ang1) and Ang2 to block their interaction with the Tie2 receptor, is under active clinical investigation.
We investigated whether suppressing the angiopoietin/Tie2 pathway, using the preclinical version of
Trebananib (mL4-3 and L1-7(N)), could increase the sensitivity of human tumor cells to immune-mediated lysis
through immunogenic modulation, which would make Trebananib a promising candidate for combination
with immunotherapy.
Methods: We assessed human carcinoma cells for expression and activation of Ang1 and Ang2 and their receptor
tyrosine kinase Tie2. In vitro, we exposed tumor cell lines expressing Tie2 to the peptibodies mL4-3 and L1-7(N), which
inhibit the binding of Ang1 and Ang2 to Tie2, and assessed the cells for changes in viability, proliferation, surface
phenotype, and sensitivity to attack by antigen-specific cytotoxic T lymphocytes (CTLs).
Results: Suppression of the angiopoietin/Tie2 pathway using mL4-3 and L1-7(N) had no effect on the proliferation or
viability of tumor cells. However, these inhibitors markedly altered tumor cell phenotype, rendering tumor cells
significantly more sensitive to antigen-specific CTL killing. ICAM-1 was shown to be mechanistically involved in
these inhibitors’ ability to sensitize tumor cells to immune-mediated attack by functional blocking studies.
Conclusion: Our findings provide a rationale for the combination of agents targeting the angiopoietin/Tie2
pathway with cancer immunotherapies.
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Background
While accumulating evidence demonstrates that cancer
vaccines are safe, their clinical efficacy needs to be im-
proved. To that end, recent studies have shown that cer-
tain antiangiogenic therapies have immunomodulatory
effects, both peripherally and within the tumor micro-
environment, that make them promising candidates for
combination with cancer immunotherapy [1–6]. For
example, the tyrosine kinase inhibitors (TKIs) sunitinib
and sorafenib have been shown to alter the immune
landscape, increasing the frequency and function of
effector immune elements while decreasing the number
or function of immune suppressor cells [7–9]. These
agents also reduce solid tumor pressure by decreasing
tumor compactness and tight junctions, allowing for im-
proved perfusion of collapsed vessels and increased
tumor oxygenation, both of which are vital to the func-
tion of immune cells [8]. Recently an additional TKI,
cabozantinib, an inhibitor of multiple receptor tyrosine
kinases, including RET, MET and VEGFR2 [10, 11], has
been reported to induce immunogenic modulation, alter-
ing tumor-cell phenotype and sensitizing tumor cells to
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immune-mediated attack [3]. In preclinical models, the
immunomodulatory actions of sunitinib, sorafenib, and
cabozantinib have had synergistic antitumor effects
when combined with immunotherapy [3].
Angiogenesis and vascular remodeling are complex
processes that involve regulation by the cytokines
angiopoietin-1 (Ang1) and Ang2, which function
through their interaction with the vascular receptor
tyrosine kinase Tie2 [12, 13]. Ang1 and Ang2 were ori-
ginally described as have opposing effects, with Ang1
functioning as a Tie2 agonist contributing to vessel
stabilization and maturation [14], and Ang2 function-
ing as an antagonist leading to vessel destabilization
[15, 16]. However, studies have since shown that, like
Ang1, Ang2 can induce Tie2 receptor phosphorylation
and promote chemotaxis, tube formation, migration,
and sprouting of endothelial cells in the absence of
Ang1, demonstrating that Ang2 can also act as an agonist
of Tie2 [13, 17, 18]. Ang2 is upregulated at sites of tumor
angiogenesis. Additionally, overexpression of Ang2 accel-
erated tumor growth and angiogenesis in some experi-
mental cancer models [19]. Clinically, high levels of Ang1
and/or Ang2 are reported in patients with breast, gastric,
ovarian, mesothelioma, and non-small cell lung cancer
and, in some cases, are associated with higher-stage dis-
ease and poor clinical outcome [20–26].
The central role of the angiopoietin/Tie2 signaling
pathway in regulating angiogenesis makes it an attract-
ive target for cancer therapies. Suppression of the Tie2
pathway using Trebananib, an investigational recom-
binant peptide-Fc fusion protein, or peptibody, that se-
lectively binds to Ang1 and Ang2 and blocks their
interaction with Tie2, is under active clinical investiga-
tion in various cancers, including breast, prostate, and
ovarian. Trebananib has been modeled in preclinical stud-
ies by combining two peptibodies, mL4-3 and L1-7(N),
which inhibit Ang1 and Ang2, respectively. In a xenograft
model of colon cancer, systemic administration of mL4-3
and L1-7(N) provided greater antitumor activity than ei-
ther agent alone, and was mechanistically involved in
reducing and rearranging tumor vasculature [15, 27]. Al-
though Tie2 was originally described as an endothelial
cell-specific receptor [28], it has since been identified in
monocytes and non-stromal cells in thyroid, breast, and
gastric cancers [29–31]. Tie2 has also been identified in a
human glioma cancer cell line and was autophosphory-
lated, suggesting constitutive activity of the Tie2 pathway
in these cells [32].
The present study investigated whether inhibiting the
Tie2 pathway in human breast, colon, prostate, and
ovarian cancer cell lines could increase the sensitivity of
tumor cells to immune-mediated lysis through immuno-
genic modulation. To our knowledge, this is the first
study to report the novel immunomodulatory effects of
targeting Tie2 directly on tumor cells. Inhibition of the
angiopoietin/Tie2 pathway, using the peptibodies mL4-3
and L1-7(N) to neutralize the binding of Ang1 and Ang2
to Tie2, rendered human carcinoma cell lines of the
breast, prostate, and ovary significantly more sensitive to
T cell-mediated attack. These findings, in addition to the
reported capacity of mL4-3 and L1-7(N) to modulate
tumor angiogenesis and induce antitumor activity preclin-
ically, provide a rationale for combining agents targeting
the angiopoietin/Tie2 axis with cancer immunotherapy.
Results
Select human tumor cells express Tie2, Ang1, and Ang2
mRNA
To analyze expression of Tie2, Ang1, and Ang2, 2
breast (MDA-MB-231 and MCF-7), 3 colon (SW620,
SW480, and Colo205), 1 prostate (LNCaP), and 1 ovar-
ian (OV17-1) human tumor cell lines were tested by
RT-PCR. Cells showed varying levels of Tie2, Ang1, and
Ang2 mRNA. Among the cell lines analyzed, only MDA-
MB-231, LNCaP, and OV17-1 had detectable levels of
Tie2 (Fig. 1). These same cell lines also expressed Ang1;
however, Ang2 was only expressed in LNCaP cells. Cell
lines expressing Tie2 and either Ang1 or Ang2 were se-
lected for further study.
The Tie2 pathway is functional in breast and ovarian
tumor cells
To investigate the activity of the Tie2 pathway in human
tumor-cell lines, we assessed OV17-1 and MDA-MB-
231 for 2 sites of phosphorylation in Tie2—py992 and
py1102—reported to be important in endotheliocytes
[33]. We measured phosphorylation of Tie2 in cultures
treated with the Ang1 inhibitor mL4-3, either alone or
in combination with exogenous recombinant Ang1, and
in cells treated with the Ang2 inhibitor L1-7(N), either
alone or in combination with exogenous recombinant
Ang2. In OV17-1 cells (Fig. 2a), phosphorylation at site
py992 was reduced by the addition of mL4-3 or L1-7(N).
Furthermore, this reduction in phosphorylation was
maintained when recombinant Ang1 or Ang2 was added
to the cultures in the presence of each inhibitor. No al-
terations in phosphorylation at site py1102 were noted
in OV17-1 cultures. In MDA-MB-231 cells (Fig. 2b),
mL4-3 reduced Tie2 phosphorylation at both the py992
and py1102 sites. This reduction was maintained when
exogenous Ang1 was added to the cells in the presence
of the inhibitor. L1-7(N) did not alter phosphorylation
in MDA-MB-231 cells at either site analyzed. These re-
sults indicate that the Tie2 pathway is active in OV17-1
and MDA-MB-231 cultures, with Ang1 and Ang2 func-
tioning through the py992 site in OV17-1 cells and
Ang1 functioning through both py992 and py1102 phos-
phorylation sites in MDA-MB-231 cells.
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Ang1 and Ang2 inhibitors do not alter cell proliferation
and viability in human tumor cells
To determine whether inhibition of the angiopoietin/
Tie2 axis has a direct proliferative or cytotoxic effect on
human tumor cells, OV17-1, MDA-MB-231, and LNCaP
tumor cells were treated in vitro for 3 days with the
Cmax of mL4-3 and L1-7(N) (16 and 10 μg/mL, respect-
ively). Both untreated and Fc-treated cells (human IgG1-
Fc at 26 μg/mL) served as controls. Relative to controls,
cell number and viability were not significantly altered
by treatment with mL4-3 and L1-7(N) in OV17-1,
MDA-MB-231, and LNCaP cultures (Fig. 3).
Ang1 and Ang2 inhibitors induce immunogenic
modulation of human carcinoma cells
It has previously been shown that treatment with cer-
tain TKIs can modulate the phenotype of immunologic-
ally relevant molecules on tumor cells, making them
more sensitive to T cell-mediated killing in a process
known as immunogenic modulation [3]. To examine
the potential of Ang1 and Ang2 inhibitors to alter
tumor phenotype, OV17-1 and MDA-MB-231 cell cul-
tures were exposed for 3 days to the Cmax of mL4-3
and L1-7(N) (16 and 10 μg/mL, respectively) or Fc con-
trol (human IgG1-Fc at 26 μg/mL) and then analyzed
for expression of human leukocyte antigen (HLA)-A2,
carcinoembryonic antigen (CEA), mucin (MUC)-1,
ICAM-1 (CD54), calreticulin, Fas (CD95), Trail-R1, and
Trail-R2. These molecules appear to enhance antitumor
T-cell responses through various mechanisms [34–38].
Relative to controls, treatment with mL4-3 and L1-7(N)
increased expression of ICAM-1, Fas, and Trail-R1 in
both OV17-1 and MDA-MB-231 cell lines. CEA and
Trail-R2 increased only in the OV17-1 cultures, while
MUC-1 and calreticulin were upregulated only in the
MDA-MB-231 cultures (Table 1). Among all the mole-
cules examined, ICAM-1 was most robustly altered
(42 % increase in mean fluorescence intensity (MFI))
following treatment in OV17-1 cultures, while calreti-
culin had the greatest increase in percentage (50 %) fol-
lowing treatment in MDA-MB-231 cells.
Ang1 and Ang2 inhibitors increase the sensitivity of
human tumor cell lines to T cell-mediated killing
To determine the functional significance of the pheno-
typic changes induced by Ang1 and Ang2 inhibitors, we
next evaluated the potential of mL4-3 and L1-7(N) to
modify the sensitivity of human tumor cells to lysis by
CD8+ cytotoxic T lymphocytes (CTLs). OV17-1, MDA-
MB-231, and LNCaP cells were exposed for 3 days to
Fig. 1 RNA expression of Ang1, Ang2, and Tie2 in human tumor cell lines. Seven human tumor cell lines were evaluated by RT-PCR for RNA
expression of Ang1, Ang2, and Tie2. Data were normalized to GAPDH. Bars indicate mean ± SEM
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mL4-3 and L1-7(N) and then used as targets in a CTL
killing assay. OV17-1 cells that were untreated or treated
with the Fc control were killed by CEA- and MUC-1-
specific T cells at a low level (Fig. 4a). Pretreatment of
these targets with the Ang1 and Ang2 inhibitors in-
creased killing by CEA- and MUC-1-specific T cells 5.1-
and 2.8-fold, respectively. MDA-MB-231 and LNCaP
cultures that were untreated or treated with the Fc
Fig. 2 Activation of Tie2 pathway in human tumor cell lines. Tie2 phosphorylation at sites py992 and py1102 and the ability of Ang1 (mL4-3) and
Ang2 (L1-7(N) inhibitors to reduce activation of the Tie2 pathway were evaluated by flow cytometry in OV17-1 (a) and MDA-MB-231 (b) tumor cell
lines. A range of concentrations of mL4-3 (0.017–170 μg/mL) and L1-7(N) (0.0407–407 μg/mL) were tested, with no dose-dependent effects noted.
Data are shown at 17 μg/mL and 4.07 μg/mL for mL-4-3 and L1-7(N), respectively. Exogenous recombinant Ang1 or Ang2 (2 μg/mL) was added
where indicated. Tumor cells were treated for 30 min at 37 °C, then harvested and stained to assess Tie2 phosphorylation
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control were lysed by CEA-specific CTLs at a level of
45 and 21 %, respectively. However, upon treatment
with mL4-3 and L1-7(N), MDA-MB-231 and LNCaP
targets were killed to a greater extent by CEA-specific
T cells, with levels of 65 and 60 % lysis, respectively.
These data indicate that exposing a variety of human
tumor cells to Ang1 and Ang2 inhibitors enhances
antigen-specific CTL-mediated killing, and that this
effect extends to more than one tumor-associated
antigen (TAA).
ICAM-1 is part of the mechanism by which Ang1 and
Ang2 inhibitors mediate immunogenic modulation in
OV17-1 cells
To investigate an association between the increased
ICAM-1 expression and improved CTL lysis observed
following treatment with Ang1 and Ang2 inhibitors in
OV17-1 cultures, we included a blocking antibody
against ICAM-1 in a CTL killing assay. Pretreating
tumor-cell targets with mL4-3 and L1-7(N) significantly
increased lysis of OV17-1 cultures by CEA-specific T
Fig. 3 Ang1 and Ang2 inhibitors did not affect tumor-cell number or viability. Human ovarian cancer cells (OV17-1; a), breast cancer cells
(MDA-MB-231; b) and prostate cancer cells (LNCaP; c) were treated with the Cmax of mL4-3 and L1-7(N) (16 and 10 μg/mL, respectively) or
control (human IgG1-Fc, 26 μg/mL) for 3 days. Cells were then harvested, counted, and assessed for viability via trypan blue exclusion. Cell
number is reported as a percentage of untreated cells. Data were analyzed with an unpaired t test. p values are indicated
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cells (from 29 to 74 %), while the addition of an anti-
ICAM-1 blocking antibody, but not the corresponding
isotype control, significantly reduced lysis (from 74 to
40 %) (Fig. 5). These data demonstrate that ICAM-1 is
involved in the mechanism by which treatment with
Ang1 and Ang2 inhibitors increase CTL-mediated lysis
of tumor cells. However, while blockade of ICAM-1 in
Ang1 and Ang2 treated cultures reduced lysis, it did
not completely abrogate T cell mediated killing to pre-
treatment levels, with a trend of a difference (p = 0.051)
Table 1 Treatment with Ang1 and Ang2 inhibitors modulates the phenotype of human tumor cells
A. OV 17-1
HLA-A2 CEA MUC-1 CD54 Calreticulin CD95 Trail-R1 Trail-R2
% (MFI) % (MFI) % (MFI) % (MFI) % (MFI) % (MFI) % (MFI) % (MFI)
Control 99.4(34250) 40.7(731) 55.9(1170) 93.8(16581) 3.5(431) 57.2(691) 27.4(604) 10.1(93)
mL4-3 + L1-7(N) 99.1(34180) 40.0(872) 59.0(1124) 97.0(23584) 3.7(429) 65.3(813) 33.7(750) 10.1(107)
B. MDA-MB-231
HLA-A2 CEA MUC-1 CD54 Calreticulin CD95 Trail-R1 Trail-R2
% (MFI) % (MFI) %(MFI) % (MFI) % (MFI) % (MFI) % (MFI) % (MFI)
Control 98.7(62083) 40.2(671) 56.0(2268) 97.9(30985) 10.6(377) 35.1(438) 44.0(775) 35.1(367)
mL4-3 + L1-7(N) 99.1(60495) 43.7(666) 59.4(2670) 99.1(35652) 15.9(428) 41.2(493) 48.7(797) 30.5(292)
The human ovarian cancer cell line OV17-1 (A), and human breast cancer cell line MDA-MB-231 (B) were treated with the Cmax of mL4-3 and L1-7(N) (16 and 10 μg/mL,
respectively) or control (human IgG1-Fc at 26 μg/mL) for 3 days
Cells were then harvested and analyzed by flow cytometry for expression of surface markers reported to be involved in CTL lysis (HLA-A2, CEA, MUC-1, ICAM-1,
calreticulin, Fas, Trail-R1 and Trail-R2). Data indicate percentage of positive cells; MFI is in parentheses. Gating was performed using isotype controls
Bold values indicate marker upregulation of > 10 % in percentage or MFI compared to controls
Fig. 4 Ang1 and Ang2 inhibitors increased CTL-mediated lysis of human tumor cells. Human ovarian cancer cells (OV17-1; a), breast cancer cells
(MDA-MB-231; b) and prostate cancer cells (LNCaP; c) were treated with the Cmax of mL4-3 and L1-7(N) (16 and 10 μg/mL, respectively) or control
(human IgG1-Fc at 26 μg/mL or no treatment) for 3 days. Cells were labeled with 111In and co-incubated with CEA-specific CD8+ T cells at an effector:
target ratio of 30:1 or MUC-1-specific CD8+ T cells at an effector:target ratio of 15:1 for 18 h. Effectors are indicated in the graphs. Bars indicate mean ± SEM.
Statistical analyses were performed with an unpaired t test. p values < 0.05 were considered significant
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noted between these groups, suggesting that other po-
tential mechanisms of action may be involved.
Discussion
The central role of the angiopoietin/Tie2 signaling path-
way in regulating angiogenesis makes it a therapeutically
attractive target for cancer therapies. The relatively
recent finding that Tie2 can be expressed in non-
endothelial cells, including tumor cells [28], has led to
renewed interest in the role of the angiopoietin/Tie2
pathway in cancer progression. The present study inves-
tigated whether suppressing the angiopoietin/Tie2 path-
way in tumor cells could increase the sensitivity of
tumor cells to immune-mediated lysis through immuno-
genic modulation. In this study, we first determined the
expression of Ang1 and 2, as well Tie2, in a panel of hu-
man tumor cell lines, and then examined the functional
consequence of inhibiting the angiopoietin/Tie2 pathway
only in cells that expressed Tie2 and either Ang1 or 2.
We show for the first time that human breast (MDA-
MB-231), prostate (LNCaP), and ovarian (OV17-1) can-
cer cell lines express measureable levels of Tie2 and
varying levels of Ang1 and Ang2 (Fig. 1). In addition,
two of the cell lines analyzed showed activation of the
Tie2 pathway (Fig. 2), with phosphorylation detected at
sites of Tie2 that have been previously described in
endothelial cells [13, 33, 39]. Specifically, in OV17-1 cul-
tures both Ang1 and Ang2 signaled through Tie2, and
inhibitors of Ang1 (mL4-3) or Ang2 (L1-7(N)) reduced
phosphorylation at site py992, but not py1102, of Tie2.
In contrast, in MDA-MB-231 cells only Ang1 signaled
through Tie2, and mL4-3 reduced phosphorylation at
sites py992 and py1102 of Tie2.
To date, the Ang1 and Ang2 inhibitors mL4-3 and
L1-7(N) have been tested primarily in vivo. They have
been shown to suppress tumor growth in mouse xenograft
models and to modulate angiogenesis by reducing tumor
vessels and normalizing remaining vessels [27, 40]. Here
we demonstrate that treatment of human tumor cell lines
in vitro with inhibitors of Ang1 and Ang2 does not alter
cell number or viability (Fig. 3), indicating that these
agents are not directly cytotoxic. However, treatment of
cells with the combination of mL4-3 and L1-7(N) mod-
ulated tumor-cell phenotype, increasing the surface ex-
pression (either percentage or MFI) of CEA, MUC-1,
ICAM-1, Fas, Trail-R1, Trail-R2, and calreticulin (Table 1).
Each of these immunologically relevant molecules is in-
volved in the cell-to-cell interaction by which CTLs kill
tumor cells [35–38]. For example, ICAM-1 is a surface
glycoprotein with both costimulatory and adhesive prop-
erties. Increased ICAM-1 levels have been correlated with
CTLs binding to tumor cells and enhancing cytotoxicity
[41–43]. Calreticulin is an intracellular protein that
translocates to the cell surface in response to several
stimuli, acting as a phagocytic signal for dendritic cells
and making antigen presentation more efficient. Trans-
location of calreticulin to the outer membrane of dying
cells was originally described to occur during immuno-
logic cell death [44, 45]; however, translocation of this
molecule to the cell surface has also been described to
occur in non-dying cells that are undergoing immuno-
genic modulation [36], where exposure of tumor cells to
certain chemotherapies and radiation, induces phenotypic
changes in viable cells that makes them more susceptible
to immune mediated killing. Upregulation of TAAs such
as CEA and MUC-1 in tumor cells may also increase the
efficiency of immune surveillance.
Consistent with the observed phenotypic modifica-
tion of tumor cells by Ang1 and Ang2 inhibitors, we
show for the first time that the sensitivity of tumor cells
to antigen-specific T-cell lysis significantly increased in
vitro (Fig. 4). Furthermore, in human ovarian cancer
cells (OV17-1) a neutralizing antibody blocking ICAM-1
ameliorated the enhanced CTL lysis seen with Ang1
and Ang2 inhibitors, demonstrating that ICAM-1 was
mechanistically involved in the increase in antigen-
specific T-cell lysis (Fig. 5). It is likely, however, that
upregulation of ICAM-1 is not the only mechanism by
Fig. 5 ICAM-1 blockade reduced the enhanced CTL lysis noted with
Ang1 and Ang2 inhibitors. Human ovarian cancer cells (OV17-1)
were treated with the Cmax of mL4-3 and L1-7(N) (16 and 10 μg/mL,
respectively) or control (no treatment) for 3 days. Tumor cells treated
for 3 days with Ang1 and Ang2 inhibitor were then pretreated for 1 h
and co-incubated during the CTL assay with anti-ICAM-1 antibody
(10 μg/mL) or the corresponding isotype control. Cells were labeled
with 111In and co-incubated with CEA-specific CD8+ T cells at an
effector: target ratio of 30:1 for 18 h. Bars indicate mean ± SEM.
Statistical analyses were performed with an unpaired t test. p
values < 0.05 were considered significant
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which blockade of Ang1 and Ang2 increased the sensi-
tivity of tumor cells to CTL mediated lysis. Blockade of
ICAM-1 in cells treated with Ang1 and Ang2 did not
completely abrogate T cell mediated killing to pre-
treatment levels, leaving room for other mechanisms.
Additionally, as the adhesive interaction of ICAM-1
with LFA-1 plays a key role in formation of the im-
munologic synapse, blockade of ICAM-1 is well known
to prevent formation of the immunologic synapse, and
thus the binding of death ligands to death receptors.
We show for the first time that inhibition of the angio-
poietin/Tie2 axis in human tumor cells, using the pre-
clinical version of Trebananib, induces immunogenic
modulation and increases the susceptibility of tumor
cells to antigen-specific lysis. Determining whether ex-
posure of human tumor cells to Ang1 and Ang2 inhibi-
tors similarly increases their susceptibility to non-
antigen-specific and/or non-immune-mediated killing
will require further testing. Additionally, as the present
study examined the functional repercussion of inhibit-
ing the angiopoietin/Tie2 axis only in cell lines that
expressed this pathway, the present study does not pre-
clude the possibility that Trebananib could have off tar-
get effects that can be exploited by T cells.
A number of antiangiogenic therapies that target VEGF
and or its receptors, including bevacizumab, sorafenib,
sunitinib, and cabozantinib, have shown clinical benefit as
monotherapies in several different cancers. Bevacizu-
mab, a recombinant humanized monoclonal antibody
that blocks angiogenesis by inhibiting VEGF-A, has
been approved by the U.S. Food and Drug Administra-
tion as a treatment for ovarian cancer [46, 47]. Like the
VEGF pathway, the angiopoietin pathway involves a
tyrosine kinase receptor, Tie2, which was initially thought
to be expressed only in vascular endothelial cells [48]. Tre-
bananib, the most clinically advanced inhibitor of both
Ang1 and Ang2, is currently being tested in three phase
III studies in advanced ovarian cancer (TRINOVA-1,
NCT01204749; TRINOVA-2, NCT01281254; TRINOVA-
3, NCT01493505), as well as in phase II studies of breast
(NCT00511459, NCT01042379) and prostate cancer
(NCT01553188).
The initial rationale for using antiangiogenic agents
to treat cancer was to starve the tumor of oxygen and
nutrients, thereby inhibiting its ability to grow and
spread [49]. However, it has become increasingly clear
that hypoxia actually promotes tumor invasiveness and
metastasis [50]. Hence, it is increasingly thought that
antiangiogenic therapies may actually normalize the ab-
normal structure and function of tumor vasculature,
increasing tumor oxygenation and preventing the un-
favorable switch to a more metastatic phenotype [51].
Improved oxygenation within tumors is important for
potential combination studies with immunotherapy, as
it is well known that a hypoxic microenvironment po-
larizes inflammatory immune cells toward a suppressive
phenotype and function. Thus, antiangiogenic treat-
ments that normalize tumor vasculature may be an
effective way to potentiate immunotherapies, which re-
quire activation of tumor antigen-specific T cells, T-cell
access into the tumor, and an immune-supportive en-
vironment to sustain T-cell function [52]. Combining
antiangiogenic agents with cancer vaccines or immune
checkpoint inhibitors may be an effective strategy for
increasing the efficacy of each individual agent.
In fact, recent studies have demonstrated the ability
of a number of antiangiogenic agents, including suniti-
nib, sorafenib, and cabozantanib, to synergize with can-
cer vaccines to produce enhanced antitumor activity
[53]. In addition to their well-known vascular remodel-
ing properties, these agents were shown to mediate an-
titumor immune responses by altering the frequency or
function of immune-cell subsets in the periphery or the
tumor microenvironment [1, 3, 8]. Only one of these
agents, cabozantinib, which is an inhibitor of multiple
receptor tyrosine kinases, including RET, MET, and
VEGRF2 has been reported to induce immunogenic
modulation, altering tumor-cell phenotype and sensitiz-
ing tumor cells to immune-mediated attack [3]. To our
knowledge, there are no data available on the direct
effect of VEGF inhibition, e.g., with an agent such as
bevacizumab, on the sensitivity of human tumor cells
to immune mediated lysis. The results of this present
study, demonstrating that inhibition of the angiopoie-
tin/Tie2 axis with the preclinical version of Trebananib
(mL4-3 and L1-7 (N)) upregulates immunologically
relevant molecules and increases antigen-specific lysis
of tumor cells, support the combination of Ang1 and Ang2
inhibitors such as Trebananib with cancer immunotherapy.
Conclusion
This study revealed a novel antitumor effect of sup-
pression of the angiopoietin/Tie2 axis. We show for
the first time that human breast, prostate, and ovarian
cancer cell lines express measureable levels of Tie2,
and that treatment of these cells with the preclinical
versions of Trebananib (mL4-3 and L1-7 (N)), which
are selective peptibodies that inhibit the binding of
Ang1 and Ang2 to Tie2, mediates immunogenic modu-
lation, rendering tumor cells more susceptible to T
cell-mediated killing. Thus, taking together Trebana-
nib’s novel immune regulatory properties and well-
known vascular remodeling properties, the present
study supports the combination of Ang1 and Ang2
inhibitors with cancer immunotherapy to potentiate
antitumor activity.
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Methods
Tumor-cell lines
Human breast (MDA-MB-231 and MCF-7), colon
(SW620, SW480, and Colo205), and prostate (LNCaP)
tumor cell lines were purchased from American Type
Culture Collection (Manassas, VA) and cultured ac-
cording to the indicated protocol. The ovarian cancer
cell line OV17-1, derived from primary ovarian tumor
with endometrioid adenocarcinoma morphology, was
obtained from Onyvax (London, UK). OV17-1 cells
were cultured in complete RPMI medium (10 % fetal
bovine serum, 100 units/mL penicillin, 100 μg/mL
streptomycin, 2 mM L-glutamine). All cells were cul-
tured in a humidified atmosphere at 37 °C with 5 %
CO2.
Drug preparation and treatment
XThe peptibodies mL4-3 and L1-7(N) were provided by
Amgen (Thousand Oaks, CA) and stored at −80 °C.
These agents were designed for preclinical studies to
mimic the effect of Ttrebananib, the Ang1 and Ang2 in-
hibitor currently used in clinical trials. The drugs were
diluted with medium immediately before use at the indi-
cated concentrations. The Cmax of mL4-3 and L1-7(N)
were calculated based on murine experiments [27]. Hu-
man recombinant IgG1-Fc protein (Life Technologies,
Frederick, MD or ACROBiosystems, Newark, DE) or no
treatment served as a control in all experiments.
RT-PCR
Total RNA was isolated from breast (MDA-MB-231 and
MCF-7), colon (SW620, SW480, and Colo205), prostate
(LNCaP), and ovarian (OV17-1) tumor cell lines using the
RNeasy extraction kit (Quiagen, Valencia, CA) and
reverse-transcribed into cDNA with the Advantage RT-
PCR kit (Clontech, Mountain View, CA). cDNA (100 ng)
was evaluated by RT-PCR using primers for Ang1
(Hs00375822_m1), Ang2 (Hs01048042_m1), Tie2 (Hs009
45146_m1), and the endogenous control glyceraldehyde
3-phosphate dehydrogenase (GAPDH) (4326317E) (Ap-
plied Biosystems, Carlsbad, CA). Expression of each gene
of interest was normalized to GAPDH. The assay was
performed using the 7300 RT-4CR System (Applied
Biosystems).
Tie2 phosphorylation assay
Ovarian (OV17-1) and breast (MDA-MB-231) tumor
cells were plated in 6-well plates (2 × 105 cells/well) and
cultured with the recommended medium for 24 h.
Tumor cells were then serum-starved for 24 h and sub-
sequently treated for 30 min at 37 °C with logarithmic
concentrations of the Ang1 inhibitor (mL4-3, 0.017–
170 ng/mL) or Ang2 inhibitor (L1-7(N), 0.0407–
407 ng/mL) with or without human recombinant Ang1
or Ang2 (2 μg/mL) (R&D Systems, Minneapolis, MN).
Cells were then harvested and stained for Tie2 (AF700)
(R&D Systems), py992 (AF647), and py1102 (PE) (BD
Biosciences, San Diego, CA), following the manufac-
turer’s protocol for assessing phosphorylated intracellu-
lar proteins. Stained cells were acquired with an LSRII
flow cytometer (BD Biosciences) and analyzed using
FlowJo software (TreeStar, Inc., Ashland, OR).
Assessment of cell proliferation and viability
To investigate the effect of Ang1 and Ang2 inhibitors on
tumor-cell proliferation and viability, ovarian (OV17-1),
breast (MDA-MB-231), and prostate (LNCaP) tumor
cells were treated with the Cmax of mL4-3 and L1-7(N)
(16 and 10 μg/mL, respectively) or control (human
IgG1-Fc at 26 μg/mL) for 3 days. Cells were then har-
vested and counted via trypan blue exclusion.
Assessment of phenotypic modulation
Ovarian (OV17-1) and breast (MDA-MB-231) tumor
cells were treated with the Cmax of mL4-3 and L1-7(N)
or control (human IgG1-Fc) for 3 days. Cells were then
harvested and analyzed for changes in expression of a
number of cell-surface markers that have been reported to
be immunologically relevant [34–38]. Cells were stained for
30 min at 4 °C using the following antibodies: anti-CD54/
ICAM-1-PE, anti-CD95/Fas-FITC, anti-CD227/MUC-1-
FITC, anti-HLA-A2-PerCP-Cy5.5 (BD Biosciences), anti-
Trail-R1-PerCP, anti-Trail-R2-AF700, anti-calreticulin-PE
(R&D Systems), and anti-CEA-APC (Miltenyi Biotec, San
Diego, CA); appropriate isotype controls were used.
Live/dead-Pacific Blue (Life Technologies) was included
to discriminate viable cells. Stained cells were acquired
with an LSRII flow cytometer (BD Biosciences) and an-
alyzed using FlowJo software (TreeStar, Inc.). Isotype
staining was < 5 % for all samples analyzed. Proteins
were defined as upregulated by treatment with the
angiopoietin inhibitors if either the percentage of cells
or the MFI increased by > 10 % relative to cells treated
with the IgG1-Fc control.
CTL assay
To evaluate the ability of Ang1 and Ang2 inhibitors to
modify the sensitivity of tumor cells to lysis by CD8+
CTLs, ovarian (OV17-1), breast (MDA-MB-231), and
prostate (LNCaP) tumor cells were treated with the
Cmax of mL4-3 and L1-7(N) or control (human IgG1-Fc
or no treatment) for 3 days. Tumor cells were labeled
with 111In-labeled oxyquinoline and co-incubated with
CEA-specific CD8+ T cells at an effector:target ratio of
30:1 or MUC-1-specific CD8+ T cells at an effector:tar-
get ratio of 15:1 for 18 h. CTLs were generated and uti-
lized as described: CEA-specific CD8+ T cells recognize
the CEA peptide epitope YLSGANLNL (CAP-1) [54],
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and MUC-1-specific CD8+ T cells recognize the MUC-1
peptide epitope ALWGQDVTSV [55]. These human
CTL lines have been in culture for a long period of time,
and as such their cytotoxic activity can be variable; however,
each experiment was independently controlled. Following
incubation of CTLs with tumor targets, supernatants were
harvested and 111In release measured using a WIZARD 2
Automatic Gamma Counter (PerkinElmer, Waltham, MA).
The percentage of tumor lysis was calculated using the for-
mula: % tumor lysis = [(experimental cpm-spontaneous
cpm)/(maximum cpm-spontaneous cpm)] x 100.
CTL assay with ICAM-1 blocking antibody
Ovarian tumor cells (OV17-1) were treated with the
Cmax of mL4-3 and L1-7(N) or control (no treatment)
for 3 days. Cells were then harvested and pretreated for
1 h and co-incubated with an anti-ICAM-1 antibody
(10 μg/mL) (BD Biosciences) or the corresponding iso-
type control during the CTL assay. The CTL killing
assay was analyzed as previously described.
Statistical analysis
Statistical analysis was performed using GraphPad
Prism (GraphPad Software, La Jolla, CA). Differences
between treatments were assessed using an unpaired
Student’s t test with a 2-tailed distribution. Results are
reported as p values calculated using a confidence
interval of 95 % (p values < 0.05 are considered statisti-
cally significant).
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